BTAI Stock Summary and Trading Ideas (Bioxcel Therapeutics | NASDAQ:BTAI)

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Bioxcel Therapeutics trades on the NASDAQ stock market under the symbol BTAI.

As of June 12, 2026, BTAI stock price climbed to $1.14 with 472,248 million shares trading.

BTAI has a beta of 3.41, meaning it tends to be more sensitive to market movements. BTAI has a correlation of 0.09 to the broad based SPY ETF.

BTAI has a market cap of $35.20 million. This is considered a Sub-Micro Cap stock.

Last quarter Bioxcel Therapeutics reported $206,000 in Revenue and -$.54 earnings per share. This fell short of revenue expectation by $-157,192 and missed earnings estimates by -$.03.

In the last 3 years, BTAI traded as high as $352.88 and as low as $1.01.

The top ETF exchange traded funds that BTAI belongs to (by Net Assets): VXF.

BTAI has underperformed the market in the last year with a price return of -35.6% while the SPY ETF gained +24.1%. BTAI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -26.5% and -2.6%, respectively, while the SPY returned +11.6% and -1.9%, respectively.

BTAI support price is $1.06 and resistance is $1.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BTAI shares will trade within this expected range on the day.